Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$16.9 million.

  • Cartesian Therapeutics' Net Cash Flow fell 11282.71% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.8 million, marking a year-over-year decrease of 15416.69%. This contributed to the annual value of $136.0 million for FY2024, which is 55799.91% up from last year.
  • Cartesian Therapeutics' Net Cash Flow amounted to -$16.9 million in Q3 2025, which was down 11282.71% from -$20.1 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Net Cash Flow peaked at $132.0 million during Q3 2024, and registered a low of -$34.0 million during Q3 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Net Cash Flow value was -$6.6 million (recorded in 2024), while the average stood at $267263.2.
  • Examining YoY changes over the last 5 years, Cartesian Therapeutics' Net Cash Flow showed a top increase of 741687.12% in 2022 and a maximum decrease of 99278.35% in 2022.
  • Over the past 5 years, Cartesian Therapeutics' Net Cash Flow (Quarter) stood at -$582000.0 in 2021, then tumbled by 992.78% to -$6.4 million in 2022, then skyrocketed by 57.42% to -$2.7 million in 2023, then tumbled by 142.73% to -$6.6 million in 2024, then tumbled by 157.57% to -$16.9 million in 2025.
  • Its Net Cash Flow stands at -$16.9 million for Q3 2025, versus -$20.1 million for Q2 2025 and -$32.2 million for Q1 2025.